These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15590388)

  • 1. Infectious toxicity using alemtuzumab.
    Nosari A; Montillo M; Morra E
    Haematologica; 2004 Dec; 89(12):1415-9. PubMed ID: 15590388
    [No Abstract]   [Full Text] [Related]  

  • 2. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.
    Cheung WW; Hwang GY; Tse E; Kwong YL
    Haematologica; 2006 May; 91(5 Suppl):ECR13. PubMed ID: 16709521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab.
    Ravandi F; O'Brien S
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T
    BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
    Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA
    Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
    Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus infections following chemotherapies of the newer generation.
    Junghanss C
    Haematologica; 2005 Dec; 90(12):1591. PubMed ID: 16330430
    [No Abstract]   [Full Text] [Related]  

  • 11. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies.
    Siegal D; Xu W; Sutherland R; Kamel-Reid S; Kuruvilla J; Lipton JH; Minden M; Messner H; Gupta V
    Bone Marrow Transplant; 2008 Jul; 42(1):51-6. PubMed ID: 18372907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G
    Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab in T-cell lymphoproliferative disorders.
    Dearden CE; Matutes E
    Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab.
    Bokhari S; Das-Gupta E; Russell N; Byrne J
    Bone Marrow Transplant; 2008 Aug; 42(4):281-2. PubMed ID: 18490912
    [No Abstract]   [Full Text] [Related]  

  • 15. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
    Borthakur G; Lin E; Faderl S; Ferrajoli A; Wierda W; Giles F; Browning ML; Kantarjian H; Keating M; O'Brien S
    Cancer; 2007 Dec; 110(11):2478-83. PubMed ID: 17960607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
    Kline J; Pollyea DA; Stock W; Artz A; Rich E; Godley L; Zimmerman T; Thompson K; Pursell K; Larson RA; van Besien K
    Bone Marrow Transplant; 2006 Feb; 37(3):307-10. PubMed ID: 16400339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV: prevention of opportunistic infections.
    Ioannidis J; Wilkinson D
    Clin Evid; 2005 Jun; (13):834-53. PubMed ID: 16135281
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.
    Chakrabarti S
    Blood; 2003 Mar; 101(5):2071. PubMed ID: 12584145
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapeutic monoclonal antibodies: update on the risk of opportunistic infections].
    Rigal E; Gateault P; Lebranchu Y; Hoarau C
    Med Sci (Paris); 2009 Dec; 25(12):1135-40. PubMed ID: 20035693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.